About Evogene
Evogene is a publicly listed company based in Rehovot (Israel) founded in 2002. Developer of plant traits. It operates in the Healthcare and Agriculture sectors. The company has 117 employees. Evogene offers products and services including CPB Platform, MicroBoost, ChemPass, and GeneRator. Its focus areas include Life Sciences, Genomics, Applied Genomics and Agrigenomics. Its legal entity is Evogene Ltd.
Company details
Evogene was founded in 2002 in Rehovot, Israel, within the agrotechnology sector. Plant traits aimed at improving yield and drought tolerance in key crops are developed through plant genomics. Proprietary computational genomic technologies are employed to deliver solutions for trait enhancement, integrating biotechnology with advanced breeding techniques. Operations focus on a range of essential crops to support agricultural improvements.
- Headquarters Rehovot, Israel
- Employees 117
- Stage Public
- SectorsHealthcareAgriculture
- Email••••••••
- Phone•••• ••••
- Website evogene.com
- Social LinkedIn X Facebook
- Legal Name Evogene Ltd.
- Annual Revenue$3.85 M (USD)-30.91as on Dec 31, 2025
- Net Profit-$8.49 M (USD)48.53as on Dec 31, 2025
- EBITDA-$12.92 M (USD)24.69as on Dec 31, 2025
- Latest Funding Round$1.32M (USD), Grant
May 2023
- InvestorsEuropean Union
& 1 more
- Employee Count117
Products & Services of Evogene
Evogene offers a comprehensive portfolio of products and services, including CPB Platform, MicroBoost, ChemPass, and GeneRator.
Integrates AI and big data for predictive biology in product development.
Facilitates discovery of microbe-based life-science products.
Enables development of small molecule-based innovations.
Supports genetic element-based product creation.
Funding Insights of Evogene
- Total Rounds 4
- Last Round Grant — $1.32M
- First Round $2M
(Apr 2008)
- Investors Count 2
All 4 funding rounds of Evogene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $1.32M | Grant | – | – | – |
| May 2023 | $1.34M | Grant | – | – | |
| Jan 2016 | $980,151 | Grant | – | – | |
| Apr 2008 | $2M | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in Evogene
Evogene has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and AquAgro Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| aquagrofund.com | ||||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Evogene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evogene
36 people are tracked at Evogene (14 in leadership, 8 in board & advisors, 14 in team); the tracked headcount is 117.
| Name | Role | Group |
|---|---|---|
Ofer Haviv | President and Chief Executive Officer | Leadership |
Liat Foigel Wejgman | Vice President, Human Resources | Leadership |
Eyal Ronen | Executive Vice President, Business Development | Leadership |
Tal Katz | VP Operations | Leadership |
Amit Dor | Director of Finance | Leadership |
Nitsan Deutsch | VP Legal | Leadership |
Polina Ravzin | VP Of Finance | Leadership |
Kenny Green | Head of Investor Relations | Leadership |
Silvia Shaked | VP Experimental Technologies | Leadership |
Lital Mamon | Head of Marketing and PR | Leadership |
Nir Arbel | Chief Product Officer | Leadership |
Yaron Eldad | CFO | Leadership |
Luna Guahnich לונה גואניש | Director Of Purchasing & Import/export | Leadership |
Ziv Halamish | Director of Greenhouse Research Center | Leadership |
Leon Recanati | Board Member | Board & advisors |
Avraham Levy | Chairman of the scientific advisory board | Board & advisors |
Oded Shoseyov | Board Member | Board & advisors |
Adrian Percy | Board Member | Board & advisors |
Nir Nimrodi | Chairman Of The Board | Board & advisors |
Sarit Firon | Chairperson | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Evogene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Evogene
Evogene is a publicly listed company on the NASDAQ with ticker symbol EVGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Mar 2008
- Listed onNASDAQ: EVGN
- Listed entityEvogene Ltd.
- Exchange sectorHealth technology
- ISINIL0011050551
- Share price$0.39 (+0.96% on the day) · 2026-10-13
- Market capitalisation$6.2M
- EPS (diluted, trailing year)$-0.91
- Volume (last session)87,648
Financials of Evogene
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $3.9M | -$8.5M | -$12.9M |
| 2024 | $5.6M | -$16.5M | -$17.1M |
| 2023 | $5.6M | -$23.9M | -$23.8M |
| 2022 | $1.7M | -$26.6M | -$27.1M |
| 2021 | $930,000 | -$27.8M | -$29.3M |
Detailed financial statements for Evogene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Evogene
4 dated milestones of Evogene across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Evogene is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.0M.
- Funding Latest funding round, Grant, of $1.3M.
Web traffic of Evogene
The website of Evogene (evogene.com) receives about 6.1K visits a month.
- Monthly visits6.1K
▲ 46.3% vs previous month
Websites whose visitors overlap most with Evogene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sponser.co.il | sponser.co.il | 100% | #87,044 | – | |
| ibioinc.com | 64% | 8.5K | #2,555,895 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evogene
Complete news archive for Evogene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evogene
Evogene was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Evogene is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
Evogene has 117 employees.
Annual revenue of Evogene is $3.85M as on Dec 31, 2025.
Evogene was founded in 2002 in Rehovot, Israel, within the agrotechnology sector. Plant traits aimed at improving yield and drought tolerance in key crops are developed through plant genomics. Proprietary computational genomic technologies are employed to deliver solutions for trait enhancement, integrating biotechnology with advanced breeding techniques. Operations focus on a range of essential crops to support agricultural improvements.
Evogene offers CPB Platform, MicroBoost, ChemPass, and GeneRator.
Yes, Evogene is publicly traded on NASDAQ under the ticker symbol EVGN.
Evogene has 2 investors. Key investors include European Union, and AquAgro Fund.
Evogene operates through Evogene Ltd.